# A Trial to Study Neladenoson Bialanate Over 20 Weeks in Patients With Chronic Heart Failure With Preserved Ejection Fraction

> **NCT03098979** · PHASE2 · COMPLETED · sponsor: **Bayer** · enrollment: 305 (actual)

## Conditions studied

- Heart Failure

## Interventions

- **DRUG:** Neladenoson bialanate (BAY1067197)
- **DRUG:** Neladenoson bialanate (BAY1067197)
- **DRUG:** Neladenoson bialanate (BAY1067197)
- **DRUG:** Neladenoson bialanate (BAY1067197)
- **DRUG:** Neladenoson bialanate (BAY1067197)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03098979
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-05-10
- **Primary completion:** 2018-05-23
- **Final completion:** 2018-06-20
- **Target enrollment:** 305 (ACTUAL)
- **Last updated:** 2019-07-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03098979

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03098979, "A Trial to Study Neladenoson Bialanate Over 20 Weeks in Patients With Chronic Heart Failure With Preserved Ejection Fraction". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03098979. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*